The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2016 | Daratumumab shows remarkable benefit in relapsed or refractory multiple myeloma in the POLLUX trial
Meletios Dimopoulos
• 9 Jun 2016
Press brief by Meletios Dimopoulos, MD of the University of Athens, Athens, Greece, at the 2016 Annual Meeting of the European Association of Hematology (EHA), held in Copenhagen, Denmark.
